Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update by Crews Kristine R, Gaedigk Andrea, Dunnenberger Henry M, Leeder J Steve, Klein Teri E, Caudle Kelly E, Haidar Cyrine E, Shen Danny D, Callaghan John T, Sadhasivam Senthilkumar, Prows Cynthia A, Kharasch Evan D, Skaar Todd C in Clinical pharmacology and therapeutics (2014). PubMed

Abstract

Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are governed by CYP2D6 activity. Polymorphisms are a major cause of CYP2D6 variability. We summarize evidence from the literature supporting this association and provide therapeutic recommendations for codeine based on CYP2D6 genotype. This document is an update to the 2012 Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2D6 genotype and codeine therapy. (1)Clinical Pharmacology & Therapeutics (2014); accepted article preview online 23 January 2014 doi:10.1038/clpt.2013.254.

[ hide abstract ]

Discussed In Paper

Related In Paper